MTP   $1.1404  -18.52% Market Closed

Midatech Pharma PLC
Last Events:

2023-03-29 Trend pattern changed from нисходящий клин to нисходящий треугольник.

2023-03-29 Signal in Stochastic changed from bearish recovery to bearish. The stochastic indicator is in the oversold territory and it heading north. These factors indicate that perhaps the downside trend is coming to an end. Last signal: entry into the oversold zone.

2023-03-29 Trend pattern changed from нисходящий треугольник to нисходящий клин.

2023-03-29 Signal in Stochastic changed from bearish to bearish recovery. The stochastic indicator is in the lower part of the neutral territory and it heading south. These factors indicate that negative dynamics is recovering. Last signal: main and signal line crossing.

2023-03-28 Trend pattern changed from нисходящий клин to нисходящий треугольник.

2023-03-28 Signal in Stochastic changed from bearish recovery to bearish. The stochastic indicator is in the oversold territory and it heading north. These factors indicate that perhaps the downside trend is coming to an end. Last signal: entry into the oversold zone.

2023-03-28 Trend pattern changed from нисходящий треугольник to нисходящий клин.

2023-03-28 Signal in Stochastic changed from bearish to bearish recovery. The stochastic indicator is in the lower part of the neutral territory and it heading south. These factors indicate that negative dynamics is recovering. Last signal: main and signal line crossing.


Current temperature: 3.59
ST: 0, Cor:

Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total Sell Sell Sell
rsi Sell Sell -
macd - Sell -
stoch Sell - -
ma20 - Sell Sell
ma50 Sell - -
ma100 Sell Sell Sell
Candlestick PatternMarch 21, 2023 Bullish Harami - consists of an unusually large black body followed by a small white body contained within large black body. It is considered as a bullish pattern when preceded by a downtrend.
ISIN US59564R2031
ceo Mr. Stephen A. Stamp
Website https://www.midatechpharma.com
Biodexa Pharmaceuticals Plc, a drug delivery technology company, focuses on the research and development of medicines in the United Kingdom, rest of Europe, and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTX114, an immuno-suppressant for topical application in psoriasis; MTD211, a long-acting formulation of brexpiprazole for the treatment of schizophrenia and adjunctive treatment of major depressive disorder; and MTD219, a long-acting formulation of tacrolimus used to lower the risk of organ transplant rejection. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.